LONDON, ONTARIO--(Marketwire - August 18, 2008) - Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (OTCBB: SLXCF) is pleased to announce that its United States licensee, Watson Pharma, Inc ("Watson"), has successfully concluded the first and only placebo controlled study with Uracyst®. This study was a multi-centre, randomized, double blind, evaluation of the efficacy and safety of Uracyst versus placebo in patients with Interstitial Cystitis/Painful Bladder Syndrome. The positive results of this study provide Watson with a good solid basis, to continue to move forward on the regulatory approval pathway. With the United States of America being the largest pharmaceutical territory in the world, this is an essential first step in getting Uracyst approved for sale in this key market.
